🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jung‐Min Lee

National Institutes of Health

ORCID: 0000-0003-1280-5909

Also affiliated with Chungnam National University, National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.208Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals

JCO Global Oncology(2025)10.1200/go-24-00636
Top 65%
0.208DataRank
Top 65%3 citations

Kristen R. Ibanez, Courtney Bowen, Duncan Donohue, Ann Oluloro, Elizabeth M. Swisher +2 more

Papers

Driven by 14 papers — median percentile 35. Top paper: “BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer”.

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872
N/A
0.790DataRank · unranked
25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer

Oncogene(2022)10.1038/s41388-022-02491-8
N/A
0.464DataRank · unranked
21 citations

Sandra Burkett, Mayank Tandon, Tomomi M. Yamamoto, Nitasha Gupta, Benjamin G. Bitler +3 more

Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals

JCO Global Oncology(2025)10.1200/go-24-00636
Top 65%
0.208DataRank
Top 65%3 citations

Kristen R. Ibanez, Courtney Bowen, Duncan Donohue, Ann Oluloro, Elizabeth M. Swisher +2 more

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Cancer Medicine(2025)10.1002/cam4.71220
N/A
0.104DataRank · unranked
1 citations

Ashley Cimino‐Mathews, Stanley Lipkowitz, Min-Jung Lee, Jayakumar R. Nair, B. Brooke Solarz +9 more

Deep Learning Segmentation of Ascites on Abdominal CT Scans for Automatic Volume Quantification

Radiology Artificial Intelligence(2024)10.1148/ryai.230601
N/A
0DataRank · unranked
13 citations

Sungwon Lee, Jung‐Min Lee, Christopher Koh, Jing Xiao, Perry J. Pickhardt +2 more

PARP inhibitors in ovarian cancer

Seminars in Oncology(2024)10.1053/j.seminoncol.2024.01.001
N/A
0DataRank · unranked
9 citations

Elena Guidice, Jung‐Min Lee, Ian S. Goldlust

Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer

Scientific Reports(2024)10.1038/s41598-024-68338-2
N/A
0DataRank · unranked
1 citations

Duncan Donohue, Tyler Malys, Jung‐Min Lee, Kristen R. Ibanez

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3877
N/A
0DataRank · unranked
8 citations

Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John +15 more

Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions

Nature Communications(2025)10.1038/s41467-025-61283-2
N/A
0DataRank · unranked
7 citations

Yashpal Rawal, Anna L Palovcak-Lightbourn, Gayatri S. Ganesan, Phoebe S. Parker, Reagan A Russell +15 more

TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment

Cancer Immunology Research(2025)10.1158/2326-6066.cir-25-0438
N/A
0DataRank · unranked
5 citations

Kellsye P. Fabian, Jung‐Min Lee, James W. Hodge, Margaret R. Pruitt

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1
N/A
0DataRank · unranked
0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1893
N/A
0DataRank · unranked
21 citations

Franklin Ning, Anna Duemler, Timothy G. Myers, Kathryn Trewhitt, Irene Ekwede +24 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6
N/A
0DataRank · unranked
42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian Cancer

Cancer Research(2024)10.1158/0008-5472.can-23-1908
N/A
0DataRank · unranked
28 citations

Chih-Yuan Chiang, Jayakumar R. Nair, Kelli M. Wilson, Ken Cheng, Jung‐Min Lee +1 more